Pharmacokinetics of reconstituted human high-density lipoprotein in pigs after hemorrhagic shock with resuscitation

Critical Care Medicine

Volumn 24, Issue 3, 1996, Pages 440-444

  DiPiro, Joseph T ^a,b   Cue', Jorge I ^b   Richards, Calita S ^a,b   Hawkins, Michael L ^b   Doran, Jan E ^c   Mansberger Jr , Arlie R ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Central Laboratory in Bern   (Switzerland)

Author keywords

apolipoprot ein A I; critical illness; endotoxemia; hemorrhage; high density lipoprotein; lipopolysaccharide; pharmacokinetics; resuscitation; shock

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TOLERABILITY; HALF LIFE TIME; HEMORRHAGIC SHOCK; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; SEPSIS;

ANALYSIS OF VARIANCE; ANIMALS; APOLIPOPROTEIN A-I; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LIPOPROTEINS, HDL; RANDOM ALLOCATION; RESUSCITATION; SHOCK, HEMORRHAGIC; SWINE;

EID: 0030005684     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199603000-00013     Document Type: Article

References (16)

1. Ulevitch RJ, Johnston AR, Weinstein DB: New function for high density lipo-protein. J Clin Invest 1981; 67:827-837
2. Munford RS, Dietschy JM: Effects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis 1985; 152:177-184
3. Emancipator K, Csako G, Elin RJ: In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60:596-601
4. Flegel WA, Wolpl A, Mānnel DN, et al: Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57: 2237-2245
5. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, et al: Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990; 58:2375-2382
6. Hubsch AP, Powell FS, Lerch PG, et al: A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxeraic rabbits. J Circ Shock 1993; 40:14-23
7. Cue' JI, DiPiro JT, Brunner LJ, et al: Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor-α responses to lipopolysaccharide in rabbits. Arch Surg 1994; 129:193-197
8. Levine DM, Parker TS, Donnelly TM, et al: In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90:12040-12044
9. Eichbaum EB, Harris HW, Kane JP, et al: Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991; 51: 413-416
10. Harris HW, Grunfeld C, Feingold KR, et al: Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86:696-702
11. Harris HW, Grunfeld C, Feingold KR, et al: Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91:1028-1034
12. Traverse LW, Moore CC, Tillman FJ: A clinically applicable exsanguination model in swine. Circ Shock 1984; 12:1-7
13. DiPiro JT, Hooker KD, Sherman JC, et al: Effect of experimental hemorrhagic shock on hepatic drug elimination. Crit Care Med 1992; 20:810-815
14. Lerch PG, Morgenthaler J-J, Peitsch MC, et al: Isolation and properties of apolipoprotein A for therapeutic use. Protides of the Biologic Fluids 1989; 36:409-416
15. Chen PS, Albers JJ: Characterization of proteoliposomes containing apoA-I: A new substrate for the measurement of lecithin: Cholesterol acyltransferase activity. J Lipid Res 1982; 23:680-691
16. Quezado ZMN, Hoffman WD, Banks SM, et al: Therapeutic trial of reconstituted human high density lipoprotein in a dog model of Gram-negative septic shock: Preliminary results. Abstr. Crit Care Med 1993; 21:S227